Insider Buying: The Oncology Institute, Inc. (NASDAQ:TOI) CEO Acquires 22,640 Shares of Stock

The Oncology Institute, Inc. (NASDAQ:TOI) CEO Daniel Virnich bought 22,640 shares of the business’s stock in a transaction dated Wednesday, March 26th. The stock was acquired at an average cost of $1.04 per share, for a total transaction of $23,545.60. Following the completion of the acquisition, the chief executive officer now directly owns 724,363 shares in the company, valued at approximately $753,337.52. This trade represents a 3.23 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Oncology Institute Trading Up 2.7 %

NASDAQ TOI opened at $1.14 on Friday. The Oncology Institute, Inc. has a one year low of $0.13 and a one year high of $1.63. The firm has a market cap of $86.14 million, a PE ratio of -1.46 and a beta of 0.41. The firm’s fifty day moving average is $0.86 and its two-hundred day moving average is $0.48. The company has a debt-to-equity ratio of 5.91, a quick ratio of 2.27 and a current ratio of 2.49.

Oncology Institute (NASDAQ:TOI) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.06). Oncology Institute had a negative return on equity of 186.83% and a negative net margin of 17.63%. The company had revenue of $100.27 million for the quarter, compared to analysts’ expectations of $109.15 million.

Institutional Trading of Oncology Institute

Several hedge funds have recently modified their holdings of TOI. HighTower Advisors LLC raised its position in Oncology Institute by 190.8% in the third quarter. HighTower Advisors LLC now owns 81,362 shares of the company’s stock worth $27,000 after acquiring an additional 53,382 shares in the last quarter. Jane Street Group LLC lifted its stake in shares of Oncology Institute by 613.6% in the fourth quarter. Jane Street Group LLC now owns 127,659 shares of the company’s stock valued at $39,000 after purchasing an additional 109,769 shares during the period. Virtu Financial LLC purchased a new stake in Oncology Institute during the fourth quarter worth about $41,000. Renaissance Technologies LLC grew its position in Oncology Institute by 7.1% during the fourth quarter. Renaissance Technologies LLC now owns 182,000 shares of the company’s stock worth $56,000 after buying an additional 12,000 shares during the period. Finally, FreeGulliver LLC increased its holdings in Oncology Institute by 219.3% in the fourth quarter. FreeGulliver LLC now owns 600,747 shares of the company’s stock valued at $186,000 after buying an additional 412,578 shares in the last quarter. 36.86% of the stock is owned by institutional investors and hedge funds.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.